A resolution honoring the memory of Jereima "Jeri" Bustamante on the fifth anniversary of her passing.
- Last Action
- 3/30/2023
Actions
- 2024-06-12Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
- 2023-01-30Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2023-01-30Introduced in Senate
CRS Summary
As of 2023-01-30 (00)
Cap Insulin Prices Act
This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.
Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.
The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.
Cosponsors (1)
- Raphael Warnock (D-GA)
Subjects
- Digestive and metabolic diseases
- Drug therapy
- Employee benefits and pensions
- Health care costs and insurance
- Health care coverage and access
- Medicare
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.